China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire full rights to the 99mTc GSA Injection and GSA cold kit from domestic rival Rongcheng Medical Technology Wuxi Co., Ltd., for a purchase price of RMB 85 million (approximately USD 11.82 million).
The 99mTc GSA Injection is a synthetic glycoprotein created by attaching galactose residues to human serum albumin. This compound mimics natural sialylglycoprotein and binds to asialoglycoprotein receptors (ASGPR) to facilitate entry into liver cells. The injection is designed for the quantitative assessment of both total and partial liver function, aiding in the evaluation of liver performance prior to surgery, thereby guiding surgical strategies and assessing postoperative liver conditions. It is poised for market submission following the successful completion of Phase III clinical trials.- Flcube.com
